Small Cap Biotechnology
Stocks Ranked by
Market Capitalization
| Name | Market cap | Price |
Price change % |
|
|---|---|---|---|---|
176
Precision BioSciences
DTIL
$289M
| $289M | $7.57 | 5.85% |
|
177
Fulcrum Therapeutics
FULC
$288M
| $288M | $3.77 | 2.45% |
|
178
Turn Therapeutics
TTRX
$286M
| $286M | $9.35 | 7.7% |
|
179
Ocugen
OCGN
$281M
| $281M | $0.8278 | 5.24% |
|
180
Cabaletta Bio
CABA
$276M
| $276M | $1.28 | 3.76% |
|
181
Prelude Therapeutics
PRLD
$275M
| $275M | $3.45 | 1.99% |
|
182
Inovio Pharmaceuticals
INO
$268M
| $268M | $1.43 | 2.05% |
|
183
SAB Biotherapeutics
SABS
$267M
| $267M | $2.96 | 3.9% |
|
184
Q32 Bio
QTTB
$261M
| $261M | $8.71 | 1.25% |
|
185
Faeth Therapeutics
FTH
$259M
| $259M | $10.03 | 5.82% |
|
186
Rocket Pharmaceuticals
RCKT
$257M
| $257M | $2.30 | 3.77% |
|
Small Cap Biotechnology Stocks at a Glance
Biotechnology companies research and develop novel drugs and therapies, often with no products yet on the market. Clinical-trial readouts and regulatory decisions drive binary stock moves, making pipeline breadth, cash runway, and partnership deals the key variables.
There are 186 small cap Biotechnology stocks — companies in the Biotechnology industry with a market cap between $250M and $2B — worth a combined $157B.
The largest by market cap are Recursion Pharmaceuticals (RXRX) at $1.99B, Harmony Biosciences (HRMY) at $1.98B and First Tracks Biotherapeutics (TRAX) at $1.98B.
Among institutional investors, First Tracks Biotherapeutics (TRAX) drew the most net new fund positions in Q2 2026: 150 funds opened new positions.
- Combined market cap: $157B across 186 stocks.
- Small Cap: market cap between $250M and $2B.
- Largest constituent: Recursion Pharmaceuticals (RXRX), $1.99B market cap.
- Most net new fund positions in Q2 2026: First Tracks Biotherapeutics (TRAX), +150 holders.
Market caps and prices updated daily; fund activity based on aggregated SEC 13F filings for Q2 2026.